PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Fumaria officinalis did not demonstrate any benefits in the management of IBS [PMID:22363129, PMID:41599795, PMID:16173134].
A herbal cream containing F. officinalis and silymarin significantly reduced SCORAD scores, though no significant difference was observed when compared to mometasone 0.1% [PMID:35614885].
Approved in Germany for colicky pain affecting the gallbladder, biliary system, and gastrointestinal tract, although placebo-controlled studies are lacking [PMID:7672742].
Evidence summary
PubMed sources
- 1.PMID: 7672742 (1995) — [Fumaria officinalis (fumitory)--clinical applications]. · Fortschritte der Medizin
- 2.PMID: 32739338 (2020) — Diverse alkaloids and biological activities of Fumaria (Papaveraceae): An ethnomedicinal group. · Fitoterapia
- 3.PMID: 40763876 (2025) — Fumaria officinalis: Phytochemical complexity and its medicinal significance. · Fitoterapia
- 4.PMID: 22363129 (2012) — Herbal medicines for the management of irritable bowel syndrome: a comprehensive review. · World journal of gastroenterology
- 5.PMID: 39942914 (2025) — Fumaria officinalis Dust as a Source of Bioactives for Potential Dermal Application: Optimization of Extraction Procedures, Phytochemical Profiling, and Effects Related to Skin Health Benefits.